<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 12, 1999
- --------------------------------------------------------------------------------
SCICLONE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
California 0-19825 94-3116852
---------- ------- ----------
<S> <C> <C>
(State or other (Commission File No.) (IRS Employer
jurisdiction Identification No.)
of incorporation)
</TABLE>
<TABLE>
<CAPTION>
901 Mariners Island Blvd.
Suite 205
San Mateo, California 94404
- --------------------- -----
<S> <C>
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code: (650) 358-3456
<PAGE> 2
ITEM 5. OTHER EVENTS
On April 12, 1999, SciClone Pharmaceuticals, Inc. sold 445,000 shares of
its unregistered common stock to The Sigma-Tau Group for a purchase price of
$1,000,000. This purchase price represented a premium of approximately 50% over
the closing market price of SciClone's common stock at the time the sale was
negotiated and a premium of approximately 30% over the closing market price of
SciClone's common stock on the closing of the transaction. The Sigma Tau Group
may not sell the shares until April 12, 2001. In addition, The Sigma-Tau Group
was not granted any registration rights covering resale of the shares.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: April 26, 1998 SCICLONE PHARMACEUTICALS, INC.
By: /s/ Shawn K. Singh
--------------------------------
Shawn K. Singh
Senior Vice President
and Secretary
3
